9 Mn (about ₹95 Cr) in a Series A2 funding round led by 3one4 Capital, with participation from existing investor Fireside Ventures. The startup will use the fresh capital for clinical trials, supply chain improvements, R&D, and new nutrition formats. “The first is clinical trials, which are going to be run by credible CROs (contract research organisations) and are intended to be published in peer-reviewed international journals. The second is cementing our moat as a business, which is our supply chain proficiency. The third is a robust testing mechanism that allows nutritional accuracy, pesticides and heavy metals to be tested batch on batch without any human intervention,” founder and CEO Shivam Hingorani told Inc42. Ace Blend also plans to conduct shelf-stability studies at launch and six months later, which Hingorani said would help build long-term safety data on its products. “Trust is not enough” in the nutritional supplements market, he said, stressing the need for scientific evidence to support product claims. Founded in 2018 by Hingorani, and later joined by Saif Mehkri as cofounder in 2022, Ace Blend offers supplements across heart health, brain health, sleep, recovery, gut health, strength and immunity. Its portfolio comprises around 14 SKUs, including plant-based protein powders, superfood mixes, and functional health supplements. Besides its website, the startup sells its products through ecommerce and quick commerce platforms, including Amazon, Flipkart, Zepto, and Blinkit. Its website contributes around 50% of revenue, with the remainder coming from marketplaces and other ecommerce channels, Hingorani said. Ace Blend clocked 300% growth in FY26 and has a repeat purchase rate of nearly 48%, according to Hingorani.